Ellen M Zimmermann, M.D.
Associate Dean & Professor
Teaching Profile
Courses Taught
2020
BMS6634 GI and Hepatology
Board Certifications
-
GastroenterologyAmerican Board of Internal Medicine
-
Internal MedicineAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Gastroenterology
Areas of Interest
- Crohn disease
- Inflammatory Bowel Disease
- Irritable bowel syndrome
- Ulcerative colitis
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-7966-2837
Publications
2022
PLA2-Triggered Activation of Cyclosporine-Phospholipid Prodrug as a Drug Targeting Approach in Inflammatory Bowel Disease Therapy.
Pharmaceutics.
14(3)
[DOI] 10.3390/pharmaceutics14030675.
[PMID] 35336048.
2022
Prodrug-Based Targeting Approach for Inflammatory Bowel Diseases Therapy: Mechanistic Study of Phospholipid-Linker-Cyclosporine PLA2-Mediated Activation.
International journal of molecular sciences.
23(5)
[DOI] 10.3390/ijms23052673.
[PMID] 35269813.
2021
Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire.
Biomedicines.
9(9)
[DOI] 10.3390/biomedicines9091098.
[PMID] 34572293.
2021
Newly Diagnosed Patients with Inflammatory Bowel Disease: The Relationship Between Perceived Psychological Support, Health-Related Quality of Life, and Disease Activity.
Health equity.
5(1):42-48
[DOI] 10.1089/heq.2020.0053.
[PMID] 33681688.
2020
Characteristics of Faculty at Risk of Leaving Their Medical Schools: An Analysis of the StandPoint™ Faculty Engagement Survey.
Journal of healthcare leadership.
12:1-10
[DOI] 10.2147/JHL.S225291.
[PMID] 32021533.
2020
College Students with Inflammatory Bowel Disease: A Qualitative Study of Challenges Associated with College Transition and Self-Care.
Health equity.
4(1):190-197
[DOI] 10.1089/heq.2019.0053.
[PMID] 32440616.
2020
Lipids and Lipid-Processing Pathways in Drug Delivery and Therapeutics.
International journal of molecular sciences.
21(9)
[DOI] 10.3390/ijms21093248.
[PMID] 32375338.
2020
Phospholipid Cyclosporine Prodrugs Targeted at Inflammatory Bowel Disease (IBD) Treatment: Design, Synthesis, and in Vitro Validation.
ChemMedChem.
15(17):1639-1644
[DOI] 10.1002/cmdc.202000317.
[PMID] 32618133.
2019
How to Foster Academic Promotion and Career Advancement of Women in Gastroenterology.
Gastroenterology.
157(3):598-601
[DOI] 10.1053/j.gastro.2019.07.041.
[PMID] 31374216.
2019
Lipidic prodrug approach for improved oral drug delivery and therapy.
Medicinal research reviews.
39(2):579-607
[DOI] 10.1002/med.21533.
[PMID] 30320896.
2019
Molecular Modeling-Guided Design of Phospholipid-Based Prodrugs.
International journal of molecular sciences.
20(9)
[DOI] 10.3390/ijms20092210.
[PMID] 31060339.
2019
Phospholipid-Based Prodrugs for Colon-Targeted Drug Delivery: Experimental Study and In-Silico Simulations.
Pharmaceutics.
11(4)
[DOI] 10.3390/pharmaceutics11040186.
[PMID] 30995772.
2019
Pre-operative total parenteral nutrition improves post-operative outcomes in a subset of Crohn’s disease patients undergoing major abdominal surgery.
Gastroenterology report.
7(2):107-114
[DOI] 10.1093/gastro/goy033.
[PMID] 30976423.
2019
Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy.
Inflammatory bowel diseases.
25(8):1417-1427
[DOI] 10.1093/ibd/izz001.
[PMID] 30839057.
2019
Small bowel stricture is associated with abnormal motility on the cine MRI sequence in patients with Crohn’s disease.
European journal of radiology.
118:264-270
[DOI] 10.1016/j.ejrad.2019.08.001.
[PMID] 31439253.
2019
Solitary ascending colon ulcer diagnosed as gastrointestinal CMV disease.
BMJ case reports.
12(2)
[DOI] 10.1136/bcr-2018-226355.
[PMID] 30739086.
2019
The prospects of lipidic prodrugs: an old approach with an emerging future.
Future medicinal chemistry.
11(19):2563-2571
[DOI] 10.4155/fmc-2019-0155.
[PMID] 31633401.
2018
Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn’s Disease.
Radiology.
286(3):776-799
[DOI] 10.1148/radiol.2018171737.
[PMID] 29319414.
2018
Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn’s Disease.
Gastroenterology.
154(4):1172-1194
[DOI] 10.1053/j.gastro.2017.11.274.
[PMID] 29329905.
2018
Effective communication of cross-sectional imaging findings in Crohn’s disease: comparing conventional EMR reporting to a published scoring system.
Abdominal radiology (New York).
43(7):1798-1806
[DOI] 10.1007/s00261-017-1368-0.
[PMID] 29075825.
2018
Effects of Preoperative Use of Biologic Agents on Operative Outcomes in Crohn’s Disease Patients.
The American surgeon.
84(9):1526-1530
[PMID] 30268188.
2018
Perioperative Care of Patients with Inflammatory Bowel Disease: Focus on Nutritional Support.
Gastroenterology research and practice.
2018
[DOI] 10.1155/2018/7890161.
[PMID] 30344603.
2018
Prospects and Challenges of Phospholipid-Based Prodrugs.
Pharmaceutics.
10(4)
[DOI] 10.3390/pharmaceutics10040210.
[PMID] 30388756.
2018
What a medical school chair wants from the dean.
Journal of healthcare leadership.
10:33-44
[DOI] 10.2147/JHL.S158937.
[PMID] 29872359.
2017
A Fixed Stricture on Routine Cross-Sectional Imaging Predicts Disease-Related Complications and Adverse Outcomes in Patients With Crohn’s Disease
Inflammatory Bowel Diseases.
23(4):641-649
[DOI] 10.1097/MIB.0000000000001054.
2017
A Fixed Stricture on Routine Cross-sectional Imaging Predicts Disease-Related Complications and Adverse Outcomes in Patients with Crohn’s Disease.
Inflammatory bowel diseases.
23(4):641-649
[DOI] 10.1097/MIB.0000000000001054.
[PMID] 28267043.
2017
Computational modeling and in-vitro/in-silico correlation of phospholipid-based prodrugs for targeted drug delivery in inflammatory bowel disease.
Journal of computer-aided molecular design.
31(11):1021-1028
[DOI] 10.1007/s10822-017-0079-5.
[PMID] 29101519.
2017
Phospholipid-drug conjugates as a novel oral drug targeting approach for the treatment of inflammatory bowel disease.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
108:78-85
[DOI] 10.1016/j.ejps.2017.06.022.
[PMID] 28627471.
2016
Anti-TNFα alters the natural history of experimental Crohn’s disease in rats when begun early, but not late, in disease.
American journal of physiology. Gastrointestinal and liver physiology.
311(4):G688-G698
[DOI] 10.1152/ajpgi.00216.2015.
[PMID] 27562059.
2016
Phospholipid-Based Prodrugs for Drug Targeting in Inflammatory Bowel Disease: Computational Optimization and In-Vitro Correlation.
Current topics in medicinal chemistry.
16(23):2543-8
[PMID] 27086789.
2015
CT and MR enterography in Crohn’s disease: current and future applications.
Abdominal imaging.
40(5):965-74
[DOI] 10.1007/s00261-015-0360-9.
[PMID] 25637127.
2014
Effects of inflammatory bowel disease on students’ adjustment to college.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
12(12):2055-62.e1
[DOI] 10.1016/j.cgh.2014.03.032.
[PMID] 24726907.
2014
Magnetization transfer in lamellar liquid crystals.
Magnetic resonance in medicine.
72(5):1427-34
[DOI] 10.1002/mrm.25034.
[PMID] 24258798.
2014
Modern prodrug design for targeted oral drug delivery.
Molecules (Basel, Switzerland).
19(10):16489-505
[DOI] 10.3390/molecules191016489.
[PMID] 25317578.
2014
MR imaging of the small bowel in Crohn disease.
Magnetic resonance imaging clinics of North America.
22(1):13-22
[DOI] 10.1016/j.mric.2013.09.001.
[PMID] 24238129.
2014
Zimmermann EM Effects of inflammatory bowel disease on students’ adjustment to college
Clinical Gastroenterology and Hepatology.
12:2055-2062
2013
Anti-tumor necrosis factor α prevents bowel fibrosis assessed by messenger RNA, histology, and magnetization transfer MRI in rats with Crohn’s disease.
Inflammatory bowel diseases.
19(4):683-90
[DOI] 10.1097/MIB.0b013e3182802c32.
[PMID] 23429466.
2013
Crohn’s disease complicated by strictures: a systematic review.
Gut.
62(7):1072-84
[DOI] 10.1136/gutjnl-2012-304353.
[PMID] 23626373.
2013
Development of a peptidoglycan-polysaccharide murine model of Crohn’s disease: effect of genetic background.
Inflammatory bowel diseases.
19(6):1238-44
[DOI] 10.1097/MIB.0b013e31828132b4.
[PMID] 23619717.
2013
Endothelial PAS domain protein 1 activates the inflammatory response in the intestinal epithelium to promote colitis in mice.
Gastroenterology.
145(4):831-41
[DOI] 10.1053/j.gastro.2013.07.010.
[PMID] 23860500.
2013
The unfolded protein response and chemical chaperones reduce protein misfolding and colitis in mice.
Gastroenterology.
144(5):989-1000.e6
[DOI] 10.1053/j.gastro.2013.01.023.
[PMID] 23336977.
2012
A new look at Crohn’s disease: novel imaging techniques.
Current opinion in gastroenterology.
28(4):334-40
[DOI] 10.1097/MOG.0b013e3283540705.
[PMID] 22678451.
2012
Automatic vs semi-automatic global cardiac function assessment using 64-row CT.
The British journal of radiology.
85(1015):e243-53
[DOI] 10.1259/bjr/65747000.
[PMID] 22045953.
2012
Computed tomography enterography findings correlate with tissue inflammation, not fibrosis in resected small bowel Crohn’s disease.
Inflammatory bowel diseases.
18(5):849-56
[DOI] 10.1002/ibd.21801.
[PMID] 21710535.
2012
Hypoxia-inducible factor-2α activation promotes colorectal cancer progression by dysregulating iron homeostasis.
Cancer research.
72(9):2285-93
[DOI] 10.1158/0008-5472.CAN-11-3836.
[PMID] 22419665.
2012
Resveratrol causes cell cycle arrest, decreased collagen synthesis, and apoptosis in rat intestinal smooth muscle cells.
American journal of physiology. Gastrointestinal and liver physiology.
302(3):G326-35
[DOI] 10.1152/ajpgi.00083.2011.
[PMID] 22052016.
2012
Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan-polysaccharide rat model of Crohn’s disease.
Inflammatory bowel diseases.
18(4):613-23
[DOI] 10.1002/ibd.21843.
[PMID] 22431488.
2011
Choosing the right cross-sectional imaging technique: trading image quality for radiation risk.
Inflammatory bowel diseases.
17(5):1089-91
[DOI] 10.1002/ibd.21536.
[PMID] 21484960.
2011
Magnetization transfer helps detect intestinal fibrosis in an animal model of Crohn disease.
Radiology.
259(1):127-35
[DOI] 10.1148/radiol.10091648.
[PMID] 21324841.
2011
MRI of the small bowel in patients with Crohn’s disease.
Current opinion in gastroenterology.
27(2):132-8
[DOI] 10.1097/MOG.0b013e3283438e5d.
[PMID] 21297471.
2010
Adenoviral transduction of enterocytes and M-cells using in vitro models based on Caco-2 cells: the coxsackievirus and adenovirus receptor (CAR) mediates both apical and basolateral transduction.
Molecular pharmaceutics.
7(3):619-29
[DOI] 10.1021/mp9001377.
[PMID] 20235596.
2010
CT enterography of pediatric Crohn disease.
Pediatric radiology.
40(1):97-105
[DOI] 10.1007/s00247-009-1465-5.
[PMID] 19936733.
2010
Detection of colonic inflammation with Fourier transform infrared spectroscopy using a flexible silver halide fiber.
Biomedical optics express.
1(3):1014-1025
[PMID] 21258526.
2010
Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update.
Expert review of clinical immunology.
6(4):543-50
[DOI] 10.1586/eci.10.30.
[PMID] 20594127.
2008
College adjustment in University of Michigan students with Crohn’s and colitis.
Inflammatory bowel diseases.
14(9):1281-6
[DOI] 10.1002/ibd.20484.
[PMID] 18512247.
2008
Identification of symptom domains in ulcerative colitis that occur frequently during flares and are responsive to changes in disease activity.
Health and quality of life outcomes.
6
[DOI] 10.1186/1477-7525-6-69.
[PMID] 18803870.
2008
Transanal delivery of angiotensin converting enzyme inhibitor prevents colonic fibrosis in a mouse colitis model: development of a unique mode of treatment.
Surgery.
144(2):259-68
[DOI] 10.1016/j.surg.2008.03.043.
[PMID] 18656634.
2007
Computed tomographic enterography adds information to clinical management in small bowel Crohn’s disease.
Inflammatory bowel diseases.
13(3):262-8
[PMID] 17206719.
2007
The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis.
Alimentary pharmacology & therapeutics.
25(3):333-42
[PMID] 17269991.
2006
Restituting intestinal epithelial cells exhibit increased transducibility by adenoviral vectors.
The journal of gene medicine.
8(12):1379-92
[PMID] 17133338.
2005
Chimeric Ad5 vectors expressing the short fiber of Ad41 show reduced affinity for human intestinal epithelium
Molecular Pharmacology.
2(6):500-508
2005
Chimeric Ad5 vectors expressing the short fiber of Ad41 show reduced affinity for human intestinal epithelium.
Molecular pharmaceutics.
2(6):500-8
[PMID] 16323957.
2005
Increased transduction of human intestinal epithelial cells by adenoviral vectors in inflammatory bowel disease.
Inflammatory bowel diseases.
11(5):464-72
[PMID] 15867586.
2005
Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?
The American journal of gastroenterology.
100(2):355-61
[PMID] 15667493.
2005
Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?
.
100:355-361
2005
Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model.
Pharmaceutical research.
22(8):1320-30
[PMID] 16078142.
2005
Novel drug delivery strategies for the treatment of inflammatory bowel disease.
Expert opinion on drug delivery.
2(3):451-63
[PMID] 16296767.
2005
Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis.
Gut.
54(6):782-8
[PMID] 15888785.
2004
IGF-I increases IGFBP-5 and collagen alpha1(I) mRNAs by the MAPK pathway in rat intestinal smooth muscle cells.
American journal of physiology. Gastrointestinal and liver physiology.
286(5):G777-83
[PMID] 15068962.
2003
Expression of NOD2 in Paneth cells: a possible link to Crohn’s ileitis.
Gut.
52(11):1591-7
[PMID] 14570728.
2001
IGF-I and IGFBP-5 in Crohn’s disease
American Journal of Physiology.
280:G1022-G1029
2001
IGF-I and procollagen 1(I) are co-expressed in a subset of mesenchymal cells in active Crohn’s disease
.
280:G1022-G1029
2001
Insulin-like growth factor I and insulin-like growth factor binding protein 5 in Crohn’s disease.
American journal of physiology. Gastrointestinal and liver physiology.
280(5):G1022-9
[PMID] 11292612.
2000
Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver.
American journal of physiology. Gastrointestinal and liver physiology.
278(3):G447-57
[PMID] 10712265.
2000
Cimetidine absorption and elimination in rat small intestine.
Drug metabolism and disposition: the biological fate of chemicals.
28(1):65-72
[PMID] 10611142.
2000
Cimetidine absorption and elimination in the small intestine
.
28:62-72
2000
IGF-I and procollagen alpha1(I) are coexpressed in a subset of mesenchymal cells in active Crohn’s disease.
American journal of physiology. Gastrointestinal and liver physiology.
279(6):G1307-22
[PMID] 11093955.
1999
Intestinal metabolism and transport of 5-Aminosalicylate (5ASA)
.
27:479-485
1999
Intestinal metabolism and transport of 5-aminosalicylate.
Drug metabolism and disposition: the biological fate of chemicals.
27(4):479-85
[PMID] 10101143.
1999
Regulation of paracellular absorption of cimetidine and 5-aminosalicylate in rat intestine.
Pharmaceutical research.
16(11):1781-5
[PMID] 10571287.
1998
Nonviral vector-mediated thymidine kinase gene transfer and ganciclovir treatment in leiomyoma cells.
Obstetrics and gynecology.
91(5 Pt 1):735-40
[PMID] 9572221.
1997
Cloning of a novel seven transmembrane receptor highly expressed in spleen and testes
Genomics.
42(3):462-466
1997
IGF-I induces collagen and IGFBP-5 mRNA in rat intestinal smooth muscle
.
G875-G882
1997
IGF-I induces collagen and IGFBP-5 mRNA in rat intestinal smooth muscle.
The American journal of physiology.
273(4):G875-82
[DOI] 10.1152/ajpgi.1997.273.4.G875.
[PMID] 9357830.
1997
Substance P as a mediator of colonic secretory reflexes
American Journal of Physiology.
272:G238-G245
1994
Expression of insulin-like growth factor binding protein-4 and -5 mRNAs in adult rat forebrain.
The Journal of comparative neurology.
339(1):91-105
[PMID] 7508953.
1994
Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats.
Gastroenterology.
106(4):960-72
[PMID] 8144001.
1993
Enhanced growth of small bowel in transgenic mice overexpressing bovine growth hormone.
Gastroenterology.
104(4):973-80
[PMID] 7681797.
1993
Insulinlike growth factor I and interleukin 1 beta messenger RNA in a rat model of granulomatous enterocolitis and hepatitis.
Gastroenterology.
105(2):399-409
[PMID] 8335195.
1986
Demonstration of thyrotropin-releasing hormone immunoreactivity in neurons of the mouse spinal dorsal horn
The Journal of Neuroscience.
6:1194-1197
1982
Effect of immuno-therapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six year prospective study
Journal of Allergy and Clinical Immunology.
70:261-271
1981
[The excessive mortality of the male sex].
Medizinische Klinik.
76(26):729-33
[PMID] 7198715.
1981
Immuno-therapy with short ragweed fraction A:D-glutamic acid: D-lysine polymer in ragweed hayfever
Journal of Allergy and Clinical Immunology.
67:272-278
1981
Measurement of IgG blocking antibodies by interference in the radioallergosorbent test
Journal of Immunology.
126:575-579
1981
Preseasonal intranasal immunotherapy with nebulized short ragweed extract
Journal of Allergy and Clinical Immunology.
67:237-242
1980
Interference in ragweed pollen and honeybee venom radioallergosorbent tests
Journal of Allergy and Clinical Immunology.
66:386-393
Grants
Apr 2021
– Dec 2022
College-aged patients with Inflammatory Bowel Disease (IBD); addressing unique needs and improving disease outcomes.
Role: Principal Investigator
Funding: ARENA PHARMACEUTICALS
Dec 2020
ACTIVE
Project ECHO IBD
Role: Co-Project Director/Principal Investigator
Funding: PFIZER INC
May 2020
ACTIVE
SBIR – A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease.
Role: Co-Investigator
Funding: RISE THERAPEUTICS
via NATL INST OF HLTH NIDDK
Apr 2019
– Jul 2021
A Novel Probiotic Engineered for Enhanced Immunological Function for Treating Inflammatory Bowel Disease
Role: Principal Investigator
Funding: RISE THERAPEUTICS
via NATL INST OF HLTH NIAID
Jul 2018
– Jun 2019
A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease
Role: Principal Investigator
Funding: RISE THERAPEUTICS
via NATL INST OF HLTH NIDDK
Jan 2017
– Jun 2022
Drug targeting strategy for the treatment of inflammatory bowel disease a novel prodrug approach
Role: Principal Investigator
Funding: US ISRAEL BINATIONAL SCI FOU
Jun 2016
– May 2018
College Students with Inflammatory Bowel Disease: Supporting the Transition to Adult IBD care
Role: Principal Investigator
Funding: ABBVIE
Education
Research Fellowship
1992
·
University of North Carolina at Chapel Hill
Fellowship
1990
·
University of Michigan Medical Center
Residency
1987
·
University of Wisconsin Hospitals and Clinics
Internship
1985
·
University of Wisconsin Hospitals and Clinics
M.D.
1984
·
University of Wisconsin
Contact Details
Phones:
- Business:
- (352) 273-9400
Emails:
- Business:
- ezimmer2@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100214
GAINESVILLE FL 32610 - Business Street:
-
1329 SW 16TH ST RM 5260
GAINESVILLE FL 32608